688166 Stock Overview
A pharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
BrightGene Bio-Medical Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥30.35 |
| 52 Week High | CN¥41.39 |
| 52 Week Low | CN¥19.63 |
| Beta | 0.39 |
| 11 Month Change | -3.96% |
| 3 Month Change | 21.40% |
| 1 Year Change | -19.28% |
| 33 Year Change | -18.00% |
| 5 Year Change | n/a |
| Change since IPO | -32.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688166 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.8% | -1.5% | -2.1% |
| 1Y | -19.3% | -9.4% | 2.8% |
Return vs Industry: 688166 underperformed the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 688166 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 688166 volatility | |
|---|---|
| 688166 Average Weekly Movement | 12.0% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688166's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688166's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,208 | Jiandong Yuan | www.bright-gene.com |
BrightGene Bio-Medical Technology Co., Ltd., a pharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products in China. The company offers Eribulin mesylate injection, Voriconazole for injection, Entecavir tablets, Oseltamivir phosphate capsule and dry suspension, Agatroban injection, Mikafungin sodium for injection, Fondaparinux sodium injection, and Caspofungin acetate for injection. It also provides antitumor, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, cerebrovascular, iron supplement, digestion, and other APIs and intermediates.
BrightGene Bio-Medical Technology Co., Ltd. Fundamentals Summary
| 688166 fundamental statistics | |
|---|---|
| Market cap | CN¥12.81b |
| Earnings (TTM) | CN¥188.08m |
| Revenue (TTM) | CN¥1.24b |
68.1x
P/E Ratio10.3x
P/S RatioIs 688166 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688166 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.24b |
| Cost of Revenue | CN¥571.33m |
| Gross Profit | CN¥670.14m |
| Other Expenses | CN¥482.05m |
| Earnings | CN¥188.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 53.98% |
| Net Profit Margin | 15.15% |
| Debt/Equity Ratio | 91.3% |
How did 688166 perform over the long term?
See historical performance and comparison